Sacituzumab Govitecan: Antibody-drug Conjugate in Triple-negative Breast Cancer and Other Solid Tumors

Overview

Journal Drugs Today (Barc)

Specialty Pharmacology

Date 2019 Oct 5

PMID 31584574

Citations 17

Authors

K M Fenn

K Kalinsky

Affiliations

Soon will be listed here.

Abstract

Patients with metastatic triple-negative breast cancer (mTNBC) that has progressed on first-line therapy have a poor prognosis with limited therapeutic options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) that has shown promising efficacy in mTNBC. SG is comprised of SN-38, the active metabolite of irinotecan, conjugated via a hydrolyzable linker to the humanized RS7 antibody targeting trophoblast cell surface antigen 2 (Trop-2), a glycoprotein that is expressed at high levels in many epithelial solid tumors. It has received breakthrough therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pretreated mTNBC. In this review, we summarize available data regarding the pharmacology, pharmacokinetics, safety and efficacy of SG and describe ongoing and future clinical studies investigating this agent.

Citing Articles

Present and Future of Immunotherapy for Triple-Negative Breast Cancer.

Sriramulu S, Thoidingjam S, Speers C, Nyati S Cancers (Basel). 2024; 16(19).

PMID: 39409871 PMC: 11475478. DOI: 10.3390/cancers16193250.

Macrophages: Key Players in the Battle against Triple-Negative Breast Cancer.

Padzinska-Pruszynska I, Kucharzewska P, Matejuk A, Gorczak M, Kubiak M, Taciak B Int J Mol Sci. 2024; 25(19).

PMID: 39409110 PMC: 11476577. DOI: 10.3390/ijms251910781.

Unveiling FDA-approved Drugs and Formulations in the Management of Bladder Cancer: A Review.

Bansal K, Chaudhary N, Bhati H, Singh V Curr Pharm Biotechnol. 2024; 26(1):48-62.

PMID: 38797905 DOI: 10.2174/0113892010314650240514053735.

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).

Wen F, Lin T, Zhang P, Shen Y Front Oncol. 2024; 13:1233196.

PMID: 38269021 PMC: 10806139. DOI: 10.3389/fonc.2023.1233196.

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.

Liu X, Deng J, Zhang R, Xing J, Wu Y, Chen W Front Immunol. 2024; 14:1335252.

PMID: 38162667 PMC: 10755013. DOI: 10.3389/fimmu.2023.1335252.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Moon S, Govindan S, Cardillo T, DSouza C, Hansen H, Goldenberg D . Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008; 51(21):6916-26. PMC: 2661425. DOI: 10.1021/jm800719t. View

Perez E, Hillman D, Mailliard J, Ingle J, Ryan J, Fitch T . Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004; 22(14):2849-55. DOI: 10.1200/JCO.2004.10.047. View

Starodub A, Ocean A, Shah M, Guarino M, Picozzi Jr V, Vahdat L . First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clin Cancer Res. 2015; 21(17):3870-8. PMC: 4558321. DOI: 10.1158/1078-0432.CCR-14-3321. View

Younes A, Bartlett N, Leonard J, Kennedy D, Lynch C, Sievers E . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19):1812-21. DOI: 10.1056/NEJMoa1002965. View

Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L . High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol. 2011; 122(1):171-7. PMC: 3104081. DOI: 10.1016/j.ygyno.2011.03.002. View

Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi A, Bonasera V . Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2012; 32(2):222-33. DOI: 10.1038/onc.2012.36. View

Shih L, Xuan H, Aninipot R, Stein R, Goldenberg D . In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res. 1995; 55(23 Suppl):5857s-5863s. View

Lin H, Huang J, Qiu J, Zhang H, Tang X, Li H . Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol. 2012; 94(1):73-8. DOI: 10.1016/j.yexmp.2012.08.004. View

10.

Kaneda N, Nagata H, Furuta T, Yokokura T . Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990; 50(6):1715-20. View

11.

Stein R, Basu A, Chen S, Shih L, Goldenberg D . Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993; 55(6):938-46. DOI: 10.1002/ijc.2910550611. View

12.

Mathijssen R, van Alphen R, Verweij J, Loos W, Nooter K, Stoter G . Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001; 7(8):2182-94. View

13.

Cardillo T, Sharkey R, Rossi D, Arrojo R, Mostafa A, Goldenberg D . Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in -wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017; 23(13):3405-3415. DOI: 10.1158/1078-0432.CCR-16-2401. View

14.

Sharkey R, McBride W, Cardillo T, Govindan S, Wang Y, Rossi E . Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015; 21(22):5131-8. DOI: 10.1158/1078-0432.CCR-15-0670. View

15.

Stepan L, Trueblood E, Hale K, Babcook J, Borges L, Sutherland C . Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011; 59(7):701-10. PMC: 3201164. DOI: 10.1369/0022155411410430. View

16.

Heist R, Guarino M, Masters G, Purcell W, Starodub A, Horn L . Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017; 35(24):2790-2797. DOI: 10.1200/JCO.2016.72.1894. View

17.

Kweekel D, Guchelaar H, Gelderblom H . Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 2008; 34(7):656-69. DOI: 10.1016/j.ctrv.2008.05.002. View

18.

Chang C, Wang Y, Zalath M, Liu D, Cardillo T, Goldenberg D . Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Mol Cancer Ther. 2016; 15(8):1910-9. DOI: 10.1158/1535-7163.MCT-16-0219. View

19.

Guerra E, Trerotola M, Aloisi A, Tripaldi R, Vacca G, La Sorda R . The Trop-2 signalling network in cancer growth. Oncogene. 2012; 32(12):1594-600. DOI: 10.1038/onc.2012.151. View

20.

Wang J, Day R, Dong Y, Weintraub S, Michel L . Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008; 7(2):280-5. DOI: 10.1158/1535-7163.MCT-07-2003. View